Michael M Ward1. 1. Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, U.S. Department of Health and Human Services, 10 Center Drive, Bethesda, MD 20892-1828, USA.
Abstract
OBJECTIVE: To determine the prevalence of physician-diagnosed systemic lupus erythematosus (SLE) in a national population-based sample in the United States. METHODS: Data from the Third National Health and Nutrition Examination Survey (NHANES III) were used to estimate the prevalence of self-reported physician-diagnosed SLE. Adult participants (age > or = 17; sample n = 20,050) were asked if they had been diagnosed with SLE by a physician. All medications currently being taken by survey participants were recorded. Two definitions were used to classify participants with SLE: self-reported physician diagnosis and self-reported physician diagnosis and a current prescription for antimalarials, corticosteroids, or other immunosuppressive medications. RESULTS: The prevalence of SLE in adults age > or = 17 based on self-reported physician diagnosis was 241 per 100,000 (95% confidence interval [CI] 130-352). The prevalence of SLE in adults age > or = 17 based on self-reported physician diagnosis and current prescription for antimalarials, corticosteroids, or immunosuppressive medications was 53.6 per 100,000 (95% CI 12.2-95.0). Among adult women, the prevalence of treated SLE was 100 per 100,000 (95% CI 19.8-179.3). CONCLUSIONS: Projecting a prevalence of 100 per 100,000 to the population of the United States, approximately 108,300 adult women had a self-reported physician diagnosis of SLE and were receiving specific treatment in 2000. This estimate is a reasonable lower boundary, as it does not include undiagnosed persons or those not being treated with antimalarials, corticosteroids, or immunosuppressive medications.
OBJECTIVE: To determine the prevalence of physician-diagnosed systemic lupus erythematosus (SLE) in a national population-based sample in the United States. METHODS: Data from the Third National Health and Nutrition Examination Survey (NHANES III) were used to estimate the prevalence of self-reported physician-diagnosed SLE. Adult participants (age > or = 17; sample n = 20,050) were asked if they had been diagnosed with SLE by a physician. All medications currently being taken by survey participants were recorded. Two definitions were used to classify participants with SLE: self-reported physician diagnosis and self-reported physician diagnosis and a current prescription for antimalarials, corticosteroids, or other immunosuppressive medications. RESULTS: The prevalence of SLE in adults age > or = 17 based on self-reported physician diagnosis was 241 per 100,000 (95% confidence interval [CI] 130-352). The prevalence of SLE in adults age > or = 17 based on self-reported physician diagnosis and current prescription for antimalarials, corticosteroids, or immunosuppressive medications was 53.6 per 100,000 (95% CI 12.2-95.0). Among adult women, the prevalence of treated SLE was 100 per 100,000 (95% CI 19.8-179.3). CONCLUSIONS: Projecting a prevalence of 100 per 100,000 to the population of the United States, approximately 108,300 adult women had a self-reported physician diagnosis of SLE and were receiving specific treatment in 2000. This estimate is a reasonable lower boundary, as it does not include undiagnosed persons or those not being treated with antimalarials, corticosteroids, or immunosuppressive medications.
Authors: Victoria K Shanmugam; Amber Schilling; Anthony Germinario; Mihriye Mete; Paul Kim; John Steinberg; Christopher E Attinger Journal: Int Wound J Date: 2011-12-14 Impact factor: 3.315
Authors: Mary A M Rogers; Deborah A Levine; Neil Blumberg; Gwenith G Fisher; Mohammed Kabeto; Kenneth M Langa Journal: J Autoimmun Date: 2011-08-30 Impact factor: 7.094
Authors: S Sam Lim; A Rana Bayakly; Charles G Helmick; Caroline Gordon; Kirk A Easley; Cristina Drenkard Journal: Arthritis Rheumatol Date: 2014-02 Impact factor: 10.995
Authors: María J Molina; Angel M Mayor; Alejandro E Franco; Carlos A Morell; Miguel A López; Luis M Vilá Journal: J Clin Rheumatol Date: 2007-08 Impact factor: 3.517